Loading organizations...
§ Private Profile · Babraham Research Campus, Cambridge, UK
Lectus Therapeutics is a technology company.
Lectus Therapeutics develops novel pharmaceutical treatments centered on modulating ion channels. The company focuses on the discovery and development of next-generation ion channel modulators, specifically small molecules, to address a range of serious conditions. Their technical approach involves rigorous drug discovery programs aimed at identifying compounds that can precisely interact with ion channels, offering targeted therapeutic interventions.
The company was founded in 2002 in Cambridge, UK. Simon John Wallwork and Graham Angus Hone were key figures in its establishment. The foundational insight stemmed from the significant, unmet medical needs in areas where ion channel dysfunction plays a critical role, driving the mission to unlock the therapeutic potential of these complex biological targets for drug development.
Lectus Therapeutics ultimately aims to serve patients suffering from debilitating conditions such as urinary bladder disorders, chronic pain, and angina. The company’s long-term vision involves advancing innovative therapies that provide more effective and safer treatment options. They aspire to translate their deep understanding of ion channel biology into clinically relevant solutions that improve patient quality of life.
Lectus Therapeutics has raised $14.0M across 1 funding round.
Lectus Therapeutics has raised $14.0M in total across 1 funding round.
Lectus Therapeutics has raised $14.0M across 1 funding round. Most recently, it raised $14.0M Series A in February 2006.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2006 | $14M Series A | — | ALSA Ventures, Soffinova Partners | Announced |
Lectus Therapeutics Ltd was a UK-based biopharmaceutical company focused on discovering and developing novel drugs targeting ion channels to treat diseases associated with smooth muscle hyperreactivity, such as neuropathic pain and related conditions.[1][2][3] It utilized a proprietary functional proteomics screening platform called LEPTICS to identify and advance ion channel modulating compounds, aiming to transform healthcare through scientific innovation in drug discovery.[1][4] The company served patients with unmet medical needs in smooth muscle-related disorders by integrating advanced molecular biology, pharmacology, and drug screening techniques.[1]
However, Lectus Therapeutics ceased operations over a decade ago, having been dissolved on 8 January 2016, with its last accounts filed for 31 July 2013.[5]
Lectus Therapeutics was incorporated on 15 October 2002 as a private limited company (initially named Fleetness 327 Limited, then Interaction Pharmaceuticals Limited) and began operations around December 2002 to develop second-generation ion channel modulating drugs.[3][5] Founded in the UK, it drew on a management team with deep expertise in ion channel drug discovery, proteomics, chemistry, biology, finance, and legal affairs from the biotech and pharmaceutical industries, supported by a world-class scientific advisory board.[1] The idea emerged from advancing ion channel research for smooth muscle hyperreactivity, with early efforts centered on proprietary proteomics platforms like LEPTICS for drug candidate identification; no specific founders are named in available records, and the company showed initial traction through its specialized R&D approach before winding down.[1][4]
Lectus rode the early 2000s wave of proteomics and ion channel drug discovery, a trend fueled by advances in functional genomics and the need for better treatments in neuropathic pain and smooth muscle disorders amid rising chronic disease prevalence.[1][3][4] Its timing aligned with post-genome era investments in targeted therapies, leveraging UK biotech hubs for R&D; market forces like pharma's push for next-gen modulators favored its model, influencing the ecosystem by pioneering LEPTICS-like platforms that informed later screening tech in ion channel research.[1][4] Though dissolved in 2016, its contributions added to the foundational knowledge in proteomics-driven drug development within the biopharma landscape.[5]
Lectus Therapeutics represented a focused bet on ion channel innovation that advanced early-stage tools like LEPTICS but ultimately dissolved in 2016 amid challenges common to pre-clinical biotechs, such as funding or pipeline hurdles.[5] No ongoing activities exist, so its direct influence has ended; future trends in AI-enhanced proteomics and gene editing may build on similar platforms, but Lectus itself offers no path forward. This underscores the high-risk nature of early drug discovery, tying back to its original mission of healthcare transformation through bold scientific bets—lessons that persist in today's resilient biotech ecosystem.[1][5]
Lectus Therapeutics has raised $14.0M in total across 1 funding round.
Lectus Therapeutics's investors include ALSA Ventures, Soffinova Partners.